➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Medtronic
Colorcon
Baxter
Merck

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

VERQUVO Drug Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Verquvo, and when can generic versions of Verquvo launch?

Verquvo is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and eighty-two patent family members in forty-six countries.

The generic ingredient in VERQUVO is vericiguat. One supplier is listed for this compound. Additional details are available on the vericiguat profile page.

DrugPatentWatch® Generic Entry Outlook for Verquvo

Verquvo will be eligible for patent challenges on January 19, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 26, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Get Started Free

Summary for VERQUVO
International Patents:182
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 28
Patent Applications: 120
Drug Prices: Drug price information for VERQUVO
What excipients (inactive ingredients) are in VERQUVO?VERQUVO excipients list
DailyMed Link:VERQUVO at DailyMed
Drug patent expirations by year for VERQUVO
Drug Prices for VERQUVO

See drug prices for VERQUVO

DrugPatentWatch® Estimated Generic Entry Opportunity Date for VERQUVO
Generic Entry Date for VERQUVO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for VERQUVO

US Patents and Regulatory Information for VERQUVO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-001 Jan 19, 2021 RX Yes No   Get Started Free   Get Started Free   Get Started Free
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-003 Jan 19, 2021 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-002 Jan 19, 2021 RX Yes No   Get Started Free   Get Started Free   Get Started Free
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-001 Jan 19, 2021 RX Yes No   Get Started Free   Get Started Free Y Y   Get Started Free
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-002 Jan 19, 2021 RX Yes No   Get Started Free   Get Started Free   Get Started Free
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-002 Jan 19, 2021 RX Yes No   Get Started Free   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Harvard Business School
AstraZeneca
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.